#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Sarcoma Granulomatosis with polyangiitis Oesophageal adenocarcinoma stage III Neuroendocrine carcinoma of the skin Arrhythmogenic right ventricular dysplasia Leber's congenital amaurosis Renal cell carcinoma Urea cycle disorder Splenic marginal zone lymphoma Central nervous system lymphoma Duchenne muscular dystrophy gene carrier Acute promyelocytic leukaemia Rosai-Dorfman syndrome Pemphigoid Uveal melanoma More trials…

    Learn about Rare Diseases

    Noonan syndrome – Trials in Disease Basal cell naevus syndrome Malignant fibrous histiocytoma – Trials in Disease Andersen-Tawil syndrome – Treatment Antisynthetase syndrome – Life with Disease Pituitary-dependent Cushing’s syndrome Epidermolysis bullosa – Treatment Ehlers-Danlos syndrome – Life with Disease Marginal zone lymphoma Prader-Willi syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Valbenazine Ditosylate Topotecan Befiradol (18F) RO7284755 Immunoglobulin M MEGESTROL ACETATE Garadacimab Tezacaftor Varnimcabtagene Autoleucel Fluoroestradiol F-18 Vinorelbine Tartrate GRNA1599 VOROLANIB VX-407 Human Normal Immunoglobulin Human Mesenchymal Stem Cells Regtivex Mk-1088 Vibegron Nicotine More therapies…

    Learn about Your Condition

    Pulmonary sarcoidosis Small intestine leiomyosarcoma Endocarditis Cerebrovascular accident Papulopustular rosacea Renal injury Hyperphagia External cephalic version Liver disorder KBG syndrome Portal hypertension Myxoid liposarcoma Brain abscess Diabetes insipidus Rosai-Dorfman syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Wojewodzki Szpital Specjalistyczny W Bialej Podlaskiej…

Wojewodzki Szpital Specjalistyczny W Bialej Podlaskiej

Ul. Terebelska 57/65, Biala Podlaska, 21-500, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiac failure
    Investigated Drugs:
    • Balcinrenone
    • Dapagliflozin
    Austria Bulgaria Czechia Finland France Germany +9

  • Study on THIO and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • 2-Amino-9-((2R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl) Tetrahydrofuran-2-Yl)-1,4,5,9-Tetrahydro-6H-Purine-6-Thione
    • Cemiplimab
    Bulgaria Hungary Poland Romania

  • Study on Lasofoxifene, Fulvestrant, and Abemaciclib for Advanced Breast Cancer in Women and Men with ESR1 Mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Abemaciclib
    • Fulvestrant
    • Lasofoxifene
    Belgium France Germany Hungary Italy Poland +2

  • Study on Ibrutinib and Venetoclax for Patients with Untreated Chronic Lymphocytic Leukemia

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Ibrutinib
    • Venetoclax
    Czechia France Hungary Italy Poland Spain

  • Study of Lisaftoclax Alone or with Drug Combination for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Acalabrutinib
    • Ibrutinib
    • Lisaftoclax
    Hungary Poland

  • A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Abemaciclib
    • Anastrozole
    • Camizestrant
    Austria Belgium Bulgaria Croatia Czechia Estonia +10

  • A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

    Not recruiting

    3 1
    Investigated Diseases:
    • Acute myocardial infarction
    Investigated Drugs:
    • Ziltivekimab
    Bulgaria Czechia Denmark France Germany Greece +4

  • Study of Subcutaneous Nivolumab for Patients with Previously Treated Advanced or Metastatic Clear Cell Kidney Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Nivolumab
    Czechia Finland France Ireland Italy Poland +3

  • Study of RVU120 and Ruxolitinib for Patients with Intermediate or High-Risk Myelofibrosis

    Not recruiting

    2 1 1 1 1
    Investigated Drugs:
    • 7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
    • Ruxolitinib
    Italy Poland

  • Study on Trastuzumab Deruxtecan and Drug Combination for Patients with High-Risk HER2-Positive Early Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Cyclophosphamide
    • Doxorubicin
    • Paclitaxel
    Germany Italy Poland Spain
Previous Page
1 2 3 4
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!